News | November 03, 2009

CardiacAssist Expands Market Penetration of TandemHeart in Cath and EP Labs


November 3, 2009 — CardiacAssist Inc. said yesterday the Cardiovascular Institute of Stanford University Hospital and Clinics in Palo Alto, Calif., is one of the newest cardiac centers to begin using TandemHeart extracorporeal circulatory support system.

TandemHeart is now being used in nearly 90 percent of the “Best U.S. Heart & Heart Surgery Hospitals” as ranked by U.S. News & World Report, with nearly 1,800 procedures performed at nearly 150 hospitals across the United States. Last month, CardiacAssist announced record nine-month financial results for 2009 compared to results for the same period in 2008.

TandemHeart can be placed rapidly by both interventional cardiologists in a cath lab and by cardiac surgeons in an operating room to provide short-term circulatory support to patients requiring additional cardiac assistance. The device provides effective and reliable temporary circulatory support for critically ill patients. Hemodynamic support includes a high net blood-flow rate of up to 5 liters per minute in the catheterization lab or up to 8 liters per minute in the OR and is fully reimbursed by Medicare under existing DRG codes.

Abiomed and Thoratec, TandemHeart has been added to the cardiac care programs at more than 20 centers in recent months.

Of the nearly 1,800 cases performed with TandemHeart to date by heart surgeons and cardiologists, 33 percent have been for ventricular dysfunction; 28 percent have been for high-risk cardiac surgery; and 39 percent have been for percutaneous cardiac interventions, the company said.

For more information: www.cardiacassist.com


Additional Content

News | Ventricular Assist Devices (VAD)

June 19, 2024 — When electrophysiologist Eugenio Cingolani, MD, isn’t seeing patients, he can usually be found in his ...

Home June 19, 2024
Home
News | Ventricular Assist Devices (VAD)

October 31, 2023 — Tenaya Therapeutics, Inc., a clinical-stage biotechnology company with a mission to discover, develop ...

Home October 31, 2023
Home
News | Ventricular Assist Devices (VAD)

June 7, 2023 — Magenta Medical Ltd. has announced the initiation of its FDA-approved Early Feasibility Study with the ...

Home June 07, 2023
Home
News | Ventricular Assist Devices (VAD)

March 1, 2023 — Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, today ...

Home March 01, 2023
Home
News | Ventricular Assist Devices (VAD)

November 2, 2022 — For decades, left ventricular-assist devices (LVADs) have extended the lives of people whose hearts ...

Home November 02, 2022
Home
Subscribe Now